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Background
Obtaining consent in emergency situations is challenging. Proxy consent allows patients to
be recruited when they lack capacity, a common scenario in stroke patients. The rapid
intervention with glyceryl trinitrate in hypertensive stroke trial-2 (RIGHT-2) recruits patients
in the pre-hospital setting within 4 hours of stroke onset.
Methods
In RIGHT-2, informed or proxy consent is taken in the ambulance. A brief assessment of
capacity is performed by the paramedic. Patients with capacity provide consent and in
patients without capacity, proxy consent is obtained from a relative, carer or friend, or by
the paramedic, witnessed by a crew member.
Results
Of 879 participants enrolled into RIGHT-2 as of 15th December 2017, 468 (53.2%)
participants gave their own consent; proxy consent was given by a relative/carer/friend for
325 (37%) and by a paramedic for 85 (9.7%). Participants who consented themselves were
younger, had less dependency and had less severe strokes than those with proxy consent.
Participants who gave their own consent had a lower rate of intracerebral haemorrhage (9%
vs 16%) and a higher rate of non-stroke (20% vs 13%) as their final diagnosis than those
who gave proxy consent. Consenting patients had better scores for dependency, cognition,
disability and quality of life at day 90 than those recruited via proxy consent.
Conclusion
Proxy consent can ensure participants are enrolled rapidly into emergency clinical trials
where they may otherwise be excluded due to lack of capacity. These patients have more
severe strokes and therefore poorer clinical outcomes.
The RIGHT-2 trial is registered: ISRCTN26986053
